Supplements

How Does Semaglutide Work? Mechanism, Effects & What to Expect

Semaglutide is now one of the most prescribed medications in the world, yet most people using it don't fully understand why it works. It targets a hormone receptor most of us rarely hear about — and the downstream effects go well beyond appetite. Here's the science behind how semaglutide actually works.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·10 min read
semaglutideGLP-1weight lossmetabolic healthinsulin sensitivitycurcumin
How Does Semaglutide Work? Mechanism, Effects & What to Expect

How Does Semaglutide Work? Mechanism, Effects & What to Expect

Semaglutide works by mimicking GLP-1, a gut hormone that signals fullness to your brain, slows stomach emptying, and suppresses glucagon release — cutting both appetite and post-meal blood sugar spikes. It is a highly effective tool for most people with obesity or type 2 diabetes, but it is not a standalone fix: muscle loss, nutrient gaps, and rebound weight gain after stopping are real concerns that require active management.

---

What Is GLP-1 and Why Does It Matter?

GLP-1 (glucagon-like peptide-1) is an incretin hormone released by L-cells in your small intestine within minutes of eating. Its job is to orchestrate your body's post-meal response: it tells the pancreas to release insulin, tells the liver to stop dumping glucose, slows gastric emptying so nutrients absorb more gradually, and — critically — signals the hypothalamus that you are full.

The problem is that GLP-1 has a half-life of roughly 2 minutes in the bloodstream. Enzymes called DPP-4 chew it up almost instantly, so the satiety signal is short-lived. Semaglutide is a synthetic analog of GLP-1 that is 94% identical to the human hormone but has been modified to resist DPP-4 degradation. The result is a molecule with a half-life of approximately 7 days — long enough to be effective with once-weekly subcutaneous dosing (Ozempic, Wegovy) or once-daily oral dosing (Rybelsus).

---

The Four Core Mechanisms of Semaglutide

Understanding how semaglutide works requires looking at four distinct pathways it engages simultaneously:

1. Central Appetite Suppression

GLP-1 receptors are expressed in the arcuate nucleus and other hypothalamic regions that govern hunger. Semaglutide crosses the blood-brain barrier in sufficient concentrations to activate these receptors directly, reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling — the two primary hunger-promoting pathways. In the STEP 1 trial (n=1,961, 68 weeks), participants on 2.4 mg weekly semaglutide lost a mean of 14.9% of body weight compared with 2.4% on placebo, driven largely by a reduction in caloric intake of roughly 35% (Wilding et al., New England Journal of Medicine 2021; PMID: 33567185).

2. Delayed Gastric Emptying

Semaglutide slows the rate at which food leaves the stomach, extending the mechanical stretch that triggers stretch-receptor satiety signals and flattening post-meal glucose curves. This effect is most pronounced during the first few months of treatment and may attenuate somewhat with long-term use — an important nuance for anyone expecting perpetually slow digestion.

3. Insulin Secretion and Glucagon Suppression

In the pancreas, GLP-1 receptors on beta cells amplify glucose-dependent insulin secretion. The phrase "glucose-dependent" is clinically important: semaglutide only stimulates insulin when blood glucose is elevated, which is why hypoglycemia is rare in non-diabetic users. Simultaneously, semaglutide suppresses glucagon from alpha cells, reducing hepatic glucose output. In a 30-week randomized trial in type 2 diabetes patients (n=387), once-weekly semaglutide 1 mg reduced HbA1c by 1.5 percentage points versus 0.9 points for liraglutide (Ahmann et al., Diabetes Care 2018; PMID: 29246950).

4. Cardiovascular and Systemic Benefits

The SELECT trial (n=17,604, mean follow-up 39.8 months) found that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in overweight or obese adults without diabetes (Ryan et al., New England Journal of Medicine 2023; PMID: 37952131). The mechanism appears to involve reduced inflammation, lower visceral adiposity, improved endothelial function, and potentially direct GLP-1 receptor signaling in cardiac tissue.

---

Semaglutide Timeline: What to Expect Week by Week

PhaseTimeframeWhat's Happening
Dose titrationWeeks 1–16Gradual ramp from 0.25 mg to maintenance dose; nausea common
Early responseWeeks 4–8Appetite noticeably reduced; weight loss begins
Active lossMonths 2–6Peak weight loss velocity; GI side effects usually ease
PlateauMonths 6–12Loss slows as body adapts; calorie deficit narrows
Maintenance12 months+Ongoing weight maintained with continued dosing
DiscontinuationAfter stoppingAverage 2/3 of weight regained within 2 years without lifestyle support

This last row is not a scare tactic — it reflects the biology. Semaglutide is treating a chronic condition. Stopping it without replacing its appetite-moderating effect with other strategies reliably leads to regain (Wilding et al., Diabetes, Obesity and Metabolism 2022; PMID: 35441470).

---

The Muscle Loss Problem — and Why Nutrition Support Matters

One underappreciated consequence of semaglutide-induced caloric restriction is lean mass loss. In the STEP 1 trial, roughly 39% of total weight lost was lean mass — a significant proportion. Muscle loss blunts resting metabolic rate and increases long-term regain risk.

This is where nutritional strategy becomes inseparable from pharmacological strategy. Protein intake of at least 1.2–1.6 g per kg of body weight, resistance training, and targeted micronutrient support are the standard of care recommendations. Nutrients that commonly become deficient on a low-calorie, low-appetite diet include:

  • Zinc — involved in insulin receptor signaling and immune function
  • Magnesium — cofactor for over 300 enzymatic reactions; commonly depleted in people with metabolic dysregulation
  • Vitamin D3 — adipose tissue sequesters vitamin D; as fat mass drops, D3 requirements shift
  • Omega-3 fatty acids (EPA/DHA) — anti-inflammatory, support cardiovascular benefit already initiated by semaglutide
  • B vitamins — particularly B12 and folate, which can fall during low-calorie phases

If you're also dealing with slow recovery after training while on a calorie deficit, nutrient gaps — not just muscle fatigue — are frequently the underlying driver.

---

Natural Compounds That Complement GLP-1 Pathways

Semaglutide is a prescription medication. The compounds below are not substitutes — but several have research supporting their role in glucose metabolism, inflammation, and metabolic health, which makes them relevant adjuncts for people on semaglutide or those managing metabolic health without a prescription.

Curcumin (Turmeric)

Curcumin, the active polyphenol in turmeric, reduces NF-κB-driven inflammation and has shown insulin-sensitizing effects in metabolic syndrome populations. A meta-analysis of 11 RCTs (n=734) found curcumin supplementation significantly reduced fasting blood glucose (mean difference −3.26 mg/dL) and insulin resistance (HOMA-IR) in patients with metabolic syndrome or type 2 diabetes (Pivari et al., Nutrients 2019; PMID: 31277714). Bioavailability is the main limitation — standard curcumin powder has poor absorption, while piperine-enhanced or phospholipid-complexed forms show meaningfully better uptake. For a full breakdown of doses and forms, see our guide to curcumin and turmeric dosage research.

If you're wondering how long dietary turmeric and curcumin takes to produce measurable effects, the timeline and who actually benefits matters as much as the dose itself.

Ginger

Ginger (Zingiber officinale) contains gingerols and shogaols that modulate the same inflammatory pathways as curcumin, with additional evidence for gastric motility support. Given that semaglutide already slows gastric emptying, ginger's well-documented anti-nausea properties are clinically relevant — nausea is the top reported side effect of GLP-1 agonists. A 12-week RCT in type 2 diabetes patients (n=88) found 2 g daily ginger powder significantly reduced fasting blood glucose, HbA1c, and triglycerides compared with placebo (Arablou et al., International Journal of Food Sciences and Nutrition 2014; PMID: 24490949).

A Note on NMN and NAD+ Precursors

Nicotinamide mononucleotide (NMN) has attracted attention for metabolic health, partly because NAD+ declines with age and metabolic stress. While the mechanistic rationale is sound — NAD+ is a cofactor for sirtuins (SIRT1, SIRT3) that regulate mitochondrial function and insulin sensitivity — the human trial data is still early. A 2021 randomized trial in postmenopausal women with prediabetes showed NMN improved muscle insulin sensitivity and skeletal muscle remodeling (Yoshino et al., Science 2021; PMID: 34407931), but it is premature to position NMN as a GLP-1 complement. Ones does not currently stock NMN, but the sirtuin-activating pathway is an area where lifestyle inputs (caloric restriction, exercise) are still the strongest evidence-backed levers.

---

What This Means for Your Formula

Semaglutide addresses appetite and glycemic control pharmacologically — but it creates secondary nutrient demands and metabolic side-effects that a well-designed supplement protocol can help address. Here is how Ones approaches the nutritional layer for people managing metabolic health:

Omega-3 (EPA/DHA): Ones includes clinically dosed EPA/DHA in formulas flagged for cardiovascular or inflammatory support. This complements the cardiovascular risk reduction already associated with GLP-1 agonists and directly targets the residual inflammatory burden that semaglutide doesn't address.

Zinc: Ones sources zinc in a highly bioavailable form dosed to support insulin receptor signaling and immune resilience — both of which matter during aggressive caloric restriction. Zinc deficiency is frequently identified in people with obesity and type 2 diabetes before and during treatment.

Vitamin D3 + K2 (MK-7): As visceral fat drops with semaglutide treatment, vitamin D that was sequestered in adipose tissue becomes available — but baseline deficiency is so prevalent in metabolically compromised individuals that proactive D3 + K2 support remains warranted. Ones includes D3 and MK-7 in formulas where blood work confirms insufficiency, rather than applying a one-size-fits-all dose.

If you're tracking recovery quality, energy levels, or concentration alongside a weight-loss protocol, understanding what causes poor concentration and fatigue in demanding schedules can help distinguish supplement gaps from lifestyle variables.

Ones builds formulas using lab results and health history — so if you're using or considering a GLP-1 medication, the AI health practitioner accounts for the nutritional demands that come with it, rather than treating weight management as a single-variable problem.

---

Key Takeaways

  • Semaglutide mimics GLP-1 to suppress appetite centrally, slow gastric emptying, stimulate glucose-dependent insulin secretion, and suppress glucagon — four mechanisms working simultaneously.
  • Clinical trials show 10–15% mean body weight loss over 68 weeks; cardiovascular event reduction of 20% was demonstrated in a large cardiovascular outcomes trial.
  • Roughly 39% of weight lost on semaglutide is lean mass in trial data — making protein intake and resistance training non-negotiable, not optional.
  • Discontinuation without lifestyle or behavioral replacement leads to significant weight regain in most people within two years.
  • Complementary compounds like curcumin, ginger, omega-3s, zinc, and vitamin D3 address the metabolic and nutritional gaps semaglutide creates but does not fill.
  • A personalized supplement formula built from your actual lab data is a more precise nutritional complement to GLP-1 therapy than a generic multivitamin.

---

This article is for informational purposes only. Semaglutide is a prescription medication. Consult a licensed healthcare provider before starting, stopping, or adjusting any medication or supplement protocol.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading